Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
CD19-CAR-DNT Cells in Idiopathic Inflammatory Myopathies: NCT06316076 Clinical Landscape Report 2026
16 October 2026
NCT06316076 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Albumin-Bound Paclitaxel in Triple Negative Breast Cancer: NCT06318897 Clinical Landscape Report 2026
16 October 2026
NCT06318897 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in Mucosal Melanoma: NCT06319196 Clinical Landscape Report 2026
16 October 2026
NCT06319196 clinical landscape for Mucosal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Allogeneic Cytokine-Induced Memory-like Natural Killer Cells(Dana-Farber Cancer Institute) in Locally Advanced Clear Cell Renal Cell Carcinoma: NCT06318871 Clinical Landscape Report 2026
16 October 2026
NCT06318871 clinical landscape for Locally Advanced Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Everolimus in Renal Cell Carcinoma: NCT06317298 Clinical Landscape Report 2026
16 October 2026
NCT06317298 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carboplatin in Recurrent Endometrial Cancer: NCT06317311 Clinical Landscape Report 2026
16 October 2026
NCT06317311 clinical landscape for Recurrent Endometrial Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in High grade B-cell lymphoma: NCT06321289 Clinical Landscape Report 2026
16 October 2026
NCT06321289 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
JMKX-003948 in Metastatic Renal Cell Carcinoma: NCT06321250 Clinical Landscape Report 2026
16 October 2026
NCT06321250 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Mismatch repair-deficient Endometrial Carcinoma: NCT06321068 Clinical Landscape Report 2026
16 October 2026
NCT06321068 clinical landscape for Mismatch repair-deficient Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develop…
9 min read
Ipilimumab in Breast cancer recurrent: NCT06324240 Clinical Landscape Report 2026
16 October 2026
NCT06324240 clinical landscape for Breast cancer recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab biosimilar(R-Pharm) in Melanoma, Cutaneous Malignant: NCT06320353 Clinical Landscape Report 2026
16 October 2026
NCT06320353 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NST-628 in Glioma: NCT06326411 Clinical Landscape Report 2026
16 October 2026
NCT06326411 clinical landscape for Glioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.